This might be explained in part by the capacity of RSV proteins (e.g. F, G, NS1, NS2), to modulate immune responses following infection of humans.49,50 Therefore, the possibility remains that these RSV vaccine strategies may result in compromised or poorly protective immune responses in humans, as is evident following natural RSV infection. This evidence concerns the gene LZTR1 and infection.